The U.S. Food and Drug Administration has introduced a new pilot program aimed at accelerating the review process for generic drugs that are both tested and produced entirely within the United States.
This initiative, announced on Friday, seeks to promote domestic drug manufacturing and research.
Earlier this week, the FDA hosted a public meeting to outline its broader strategies to bolster U.S. pharmaceutical manufacturing.
According to the FDA, these measures are intended to enhance the U.S. drug supply chain and increase the availability of high-quality generic medications for American consumers.